Compare
Biofrontera Inc. vs Wave Life Sciences, Inc. vs Xilio Therapeutics, Inc. vs Integrated Biopharma Inc
| Latest fiscal year | Biofrontera Inc. BFRI | Wave Life Sciences, Inc. WVE | Xilio Therapeutics, Inc. XLO | Integrated Biopharma Inc INBP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-06-30 |
| Revenue | $41.70M | $42.73M | $43.77M | $43.87M |
| Revenue growth (YoY) | +11.7% | -60.5% | +589.9% | -19.3% |
| Gross margin | n/a | n/a | n/a | 1.8% |
| Operating margin | -27.2% | -504.1% | -95.9% | -6.2% |
| Net margin | -25.3% | -478.3% | -80.1% | -6.5% |
| Net income | -$10.54M | -$204.38M | -$35.04M | -$2.84M |
| EPS (Diluted) | -$1.04 | -$1.21 | -$4.19 | -$0.09 |
| Operating cash flow | -$13.36M | -$187.49M | -$4.99M | $1.24M |
| Free cash flow | -$13.36M | -$188.21M | -$5.51M | $895.0K |
| Cash & equivalents | $6.39M | $602.07M | $137.53M | $4.47M |
| Total assets | $28.56M | $638.50M | $154.69M | $25.34M |
| Total liabilities | $18.08M | $112.27M | $119.41M | $7.67M |
| Shareholders' equity | $10.48M | $518.36M | $35.27M | $17.67M |
| Return on year-end equity | -100.5% | -39.4% | -99.3% | -16.1% |
| Shares outstanding | 11.65M | 187.66M | 4.53M | 31.06M |
Revenue, most recent five fiscal years
| Fiscal year | Biofrontera Inc. | Wave Life Sciences, Inc. | Xilio Therapeutics, Inc. | Integrated Biopharma Inc |
|---|---|---|---|---|
| Latest | $41.70M Ended 2025-12-31 | $42.73M Ended 2025-12-31 | $43.77M Ended 2025-12-31 | $43.87M Ended 2026-06-30 |
| 1 year earlier | $37.32M Ended 2024-12-31 | $108.30M Ended 2024-12-31 | $6.34M Ended 2024-12-31 | $54.35M Ended 2025-06-30 |
| 2 years earlier | $34.07M Ended 2023-12-31 | $113.31M Ended 2023-12-31 | n/a | $50.32M Ended 2024-06-30 |
| 3 years earlier | $28.67M Ended 2022-12-31 | $3.65M Ended 2022-12-31 | n/a | $50.67M Ended 2023-06-30 |
| 4 years earlier | $24.10M Ended 2021-12-31 | $40.96M Ended 2021-12-31 | n/a | $56.25M Ended 2022-06-30 |